Bone biologics announces closing of $5.0 million public offering

Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), series d warrants to purchase up to 1,250,000 shares of common stock and series e short-term warrants to purchase up to 1,250,000 shares o.
BBLG Ratings Summary
BBLG Quant Ranking